Results 211 to 220 of about 38,595 (290)

GLP-1RA and the risk of non-arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes: A population-based study. [PDF]

Diabetes Obes Metab
Tesfaye H, Paik JM, Wexler DJ, Hathaway JT, Yu EW, Freedman A, Rizzo JF, Patorno E.   +7 more
europepmc   +1 more source

Unimolecular GLP‐1/Apelin Hybrid Peptides Cause Prominent Appetite Suppression, as Well as Enhancing Insulin Secretion, Beta‐Cell Survival and Glycaemic Regulation

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4706-4717, June 2026.
ABSTRACT Aim To characterise the metabolic benefits of a GLP‐1/apelin hybrid peptide, namely exendin‐4‐linker‐apelin (ELA), and associated acylated forms, including ELA‐Lys12(γGluPal), ELA‐Lys27(γGluPal) and ELA‐Lys38(γGluPal). Methods Concentration‐ and receptor‐dependent effects of the peptides on insulin secretion and beta‐cell turnover were ...
Ananyaa Sridhar, Ethan S. Palmer, Sarah L. Craig, Elzbieta Krason‐Kidzinska, Nigel Irwin, Finbarr P. M. O'Harte   +5 more
wiley   +1 more source

Impact of SGLT2i and GLP-1RA on liver-related events in patients with MASLD and type 2 diabetes: A network meta-analysis. [PDF]

JHEP Rep
Li L, Mao X, Lee CH, Wai Lui DT, Wan-Hin Hui R, Mak LY, Yuen MF, Cheung KS, Seto WK.   +8 more
europepmc   +1 more source

Association of GLP‐1 Receptor Agonists With Hepatic Decompensation in the All of Us Research Program

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4837-4846, June 2026.
ABSTRACT Aims To evaluate the association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) initiation and the risk of hepatic decompensation compared with dipeptidyl peptidase 4 inhibitors (DPP4is) in a racially and ethnically diverse cohort of adults with Type 2 diabetes.
Inyoung Hwang, Yun Kim, Sang Won Lee
wiley   +1 more source

IL-27, a metabolic regulator secreted by astrocytes in response to GLP-1RA OHP2, modulates microglial reprogramming in Alzheimer's disease by regulating cGAS lactylation. [PDF]

J Neuroinflammation
Du Y, Wu L, Mao Y, Chen S, Gao X.
europepmc   +1 more source

SEMASEARCH Study Design: Real‐World Evaluation of Semaglutide 2.4 mg in Adults With Severe Obesity Underrepresented in Clinical Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4602-4609, June 2026.
ABSTRACT Background Although semaglutide 2.4 mg has demonstrated significant weight loss efficacy in clinical trials, real‐world data, particularly with regard to clinically complex and underrepresented populations, remain limited. Objectives The study aims to assess the real‐world effectiveness and patient‐reported outcomes associated with the use of ...
Pierre Bel Lassen, David Jacobi, Marie‐Claude Brindisi, Jean‐Baptiste Bonnet, Fabien Subtil, Sylvie Bin, Fanny Abad, Christine Poitou, Bérénice Segrestin, Séverine Ledoux, Bénédicte Gaborit, Judith Aron‐Wisnewsky, Claire Carette, Mohamed Zerguine, Blandine Gatta‐Cherifi, Didier Quilliot, Emilie Montastier, Antoine Avignon, Héléna Mosbah, Sébastien Czernichow, Emmanuel Disse   +20 more
wiley   +1 more source

Gut microbiota modulation in GLP-1RA and SGLT-2i therapy: clinical implications and mechanistic insights in type 2 diabetes. [PDF]

Clin Kidney J
Kanbay M, Al-Shiab R, Shah E, Ozbek L, Guldan M, Ortiz A, Fouque D.   +6 more
europepmc   +1 more source

GLP‐1 Receptor Agonists for Obstructive Sleep Apnea: An Otolaryngologist's Prescription?

The Laryngoscope, Volume 136, Issue 6, Page 2406-2409, June 2026.
Alina Zgardau, Ryan Chin Taw Cheong, Kenny Peter Pang, Brian W. Rotenberg   +3 more
wiley   +1 more source

Interrelationship Between Baseline HbA1c, SGLT‐2 Inhibitor Use and Risk of Diabetic Ketoacidosis in Adults With Type 2 Diabetes: A Systematic Review and Meta‐Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 5217-5228, June 2026.
ABSTRACT Aims There is ongoing uncertainty about whether initiating sodium–glucose co‐transporter 2 inhibitor (SGLT‐2i) therapy in individuals with type 2 diabetes (T2D) who have elevated baseline HbA1c levels may lead to an additive or potentially synergistic increase in the risk of diabetic ketoacidosis (DKA). This systematic review and meta‐analysis
Samuel Seidu, Setor K. Kunutsor, Erwin Taguiam, Kamlesh Khunti   +3 more
wiley   +1 more source

Exploring the risk of depression and suicide/self-injury in patients receiving GLP-1RAs combined with metformin versus GLP-1RA monotherapy: a real-word analysis of the FAERS database. [PDF]

Endocr Connect
Ji W, Ma Y, Fang J, Chen L.
europepmc   +1 more source